Sydney most cancers medtech startup Lumonus, has added a further $3 million to its Sequence B, 4 months on, to take the overall raised to $28 million.
Brandon Capital and Investible joined the spherical, led by Aviron Funding Administration with assist from present investor Oncology Ventures, which backed a Seed spherical in March 2025. The preliminary $25m Sequence B elevate was introduced final November.
The medical care platform, based in 2024, makes use of AI for radiation oncology workflow automation and is used within the US, Australia and Europe. Clinicians have used it seek the advice of and prescribe on greater than 280,000 most cancers therapies, automating greater than 75,000r therapy plans.
The funds shall be used to develop the US go-to-market and medical success groups, medical informatics capabilities, and enhance its flagship merchandise, Lumonus AI Doctor and Lumonus AI Dosimetry, for extra personalised, data-driven care.
Lumonus CEO Keith Hansen stated oncology (most cancers prognosis and therapy) is at an inflection level
“Scientific innovation in most cancers therapy has superior considerably, however the programs that assist groups delivering the care haven’t stored tempo,” he stated
“By combining AI-native structure, a complete end-to-end workflow strategy, and a dedication to partnering with care groups to unravel real-world ache factors, we’re reimagining oncology workflows. This funding permits us to develop our world-class crew and assist extra well being programs which can be able to embrace a greater means.”
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our e-newsletter, and be a part of our rising group at nextbusiness24.com
